Oncology Foundation Selects Oracle Health Sciences Cloud Solutions for 10-Year Clinical Study
The Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer,.
The Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer, has selected Oracle’s Siebel Clinical Trial Management System and Oracle Health Sciences IRT as the IT platform for a comprehensive, 10-year clinical study, conducted in partnership with a tier-one pharmaceutical company and sponsored by Alliance Foundation Trials (AFT). AFT will use Siebel Clinical Trial Management System and plans to create a centralized trial management database that provides users with the most relevant information based on their specific roles and responsibilities and is designed to speed access to critical data, improve monitoring and patient safety, and keep data secure. Users can also access the system via any browser from any device, further elevating productivity and the user experience. The deployment of Oracle Health Sciences IRT is designed to enable AFT to more effectively manage patient randomization and global supply chains by extending interactive voice response (IVR) and interactive web response (IWR) systems.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
